BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 24004819)

  • 1. Mammary carcinoma cell derived cyclooxygenase 2 suppresses tumor immune surveillance by enhancing intratumoral immune checkpoint activity.
    Markosyan N; Chen EP; Evans RA; Ndong V; Vonderheide RH; Smyth EM
    Breast Cancer Res; 2013; 15(5):R75. PubMed ID: 24004819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myeloid Cell COX-2 deletion reduces mammary tumor growth through enhanced cytotoxic T-lymphocyte function.
    Chen EP; Markosyan N; Connolly E; Lawson JA; Li X; Grant GR; Grosser T; FitzGerald GA; Smyth EM
    Carcinogenesis; 2014 Aug; 35(8):1788-97. PubMed ID: 24590894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of cyclooxygenase 2 in mouse mammary epithelial cells delays breast cancer onset through augmentation of type 1 immune responses in tumors.
    Markosyan N; Chen EP; Ndong VN; Yao Y; Sterner CJ; Chodosh LA; Lawson JA; Fitzgerald GA; Smyth EM
    Carcinogenesis; 2011 Oct; 32(10):1441-9. PubMed ID: 21771729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
    Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
    Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T; Fuangthong M; Artpradit C; Ungtrakul T; Sricharunrat T; Taha F; Satayavivad J
    Eur J Pharmacol; 2021 Apr; 897():173960. PubMed ID: 33617828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunological differences between primary and metastatic breast cancer.
    Szekely B; Bossuyt V; Li X; Wali VB; Patwardhan GA; Frederick C; Silber A; Park T; Harigopal M; Pelekanou V; Zhang M; Yan Q; Rimm DL; Bianchini G; Hatzis C; Pusztai L
    Ann Oncol; 2018 Nov; 29(11):2232-2239. PubMed ID: 30203045
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 and PGE2-dependent immunomodulation in breast cancer.
    Chen EP; Smyth EM
    Prostaglandins Other Lipid Mediat; 2011 Nov; 96(1-4):14-20. PubMed ID: 21907301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 12. Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8
    Fang W; Zhou T; Shi H; Yao M; Zhang D; Qian H; Zeng Q; Wang Y; Jin F; Chai C; Chen T
    J Exp Clin Cancer Res; 2021 Jan; 40(1):4. PubMed ID: 33390170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil Extracellular Traps Promote T Cell Exhaustion in the Tumor Microenvironment.
    Kaltenmeier C; Yazdani HO; Morder K; Geller DA; Simmons RL; Tohme S
    Front Immunol; 2021; 12():785222. PubMed ID: 34899751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune phenotype of patients with stage IV metastatic inflammatory breast cancer.
    Fernandez SV; MacFarlane AW; Jillab M; Arisi MF; Yearley J; Annamalai L; Gong Y; Cai KQ; Alpaugh RK; Cristofanilli M; Campbell KS
    Breast Cancer Res; 2020 Dec; 22(1):134. PubMed ID: 33267869
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WDR5-H3K4me3 epigenetic axis regulates OPN expression to compensate PD-L1 function to promote pancreatic cancer immune escape.
    Lu C; Liu Z; Klement JD; Yang D; Merting AD; Poschel D; Albers T; Waller JL; Shi H; Liu K
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34326167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CaMKK2 in myeloid cells is a key regulator of the immune-suppressive microenvironment in breast cancer.
    Racioppi L; Nelson ER; Huang W; Mukherjee D; Lawrence SA; Lento W; Masci AM; Jiao Y; Park S; York B; Liu Y; Baek AE; Drewry DH; Zuercher WJ; Bertani FR; Businaro L; Geradts J; Hall A; Means AR; Chao N; Chang CY; McDonnell DP
    Nat Commun; 2019 Jun; 10(1):2450. PubMed ID: 31164648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transforming growth factor beta orchestrates PD-L1 enrichment in tumor-derived exosomes and mediates CD8 T-cell dysfunction regulating early phosphorylation of TCR signalome in breast cancer.
    Chatterjee S; Chatterjee A; Jana S; Dey S; Roy H; Das MK; Alam J; Adhikary A; Chowdhury A; Biswas A; Manna D; Bhattacharyya A
    Carcinogenesis; 2021 Feb; 42(1):38-47. PubMed ID: 32832992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COX-2 Inhibitors Decrease Expression of PD-L1 in Colon Tumors and Increase the Influx of Type I Tumor-infiltrating Lymphocytes.
    Cecil DL; Gad EA; Corulli LR; Drovetto N; Lubet RA; Disis ML
    Cancer Prev Res (Phila); 2022 Apr; 15(4):225-231. PubMed ID: 34987061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
    Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
    Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.